These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38181813)

  • 1. Is Exudative Neovascular AMD a Chronic Disease? Analysis of Long-term Progression under Anti-VEGF Therapy.
    Gunnemann ML; Ziegler M; Book M; Gunnemann F; Rothaus K; Spital G; Gutfleisch M; Lange C; Lommatzsch AP; Pauleikhoff D
    Klin Monbl Augenheilkd; 2024 Jul; ():. PubMed ID: 38181813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years].
    Bodénès F; Massé H; Lebreton O; Weber M
    J Fr Ophtalmol; 2021 May; 44(5):626-631. PubMed ID: 33840491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
    Lukacs R; Schneider M; Nagy ZZ; Sandor GL; Kaan K; Asztalos A; Enyedi L; Pek G; Barcsay G; Szabo A; Borbandy A; Kovacs I; Resch MD; Papp A
    BMC Ophthalmol; 2023 Mar; 23(1):110. PubMed ID: 36932356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological changes of macular neovascularization during long-term anti-VEGF-therapy in neovascular age-related macular degeneration.
    Pauleikhoff D; Gunnemann ML; Ziegler M; Heimes-Bussmann B; Bormann E; Bachmeier I; Yu S; Garcia Armendariz B; Pauleikhoff L
    PLoS One; 2023; 18(12):e0288861. PubMed ID: 38134207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-VEGF Treatment Strategies for 3 Subtypes of Neovascular Age-Related Macular Degeneration in a Clinical Setting: A Multicenter Cohort Study in Japan.
    Yoneda K; Takeuchi M; Yasukawa T; Terasaki H; Yamamoto Y; Jujo T; Wakuta M; Matsubara H; Mitamura Y; Kato A; Kondo M; Kimura K; Takagi H; Gomi F; Sakamoto T;
    Ophthalmol Retina; 2023 Oct; 7(10):869-878. PubMed ID: 37295608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
    Prahs P; Brandl C; Helbig H; Volz C
    Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
    Sunaga T; Maeda M; Saulle R; Ng SM; Sato MT; Hasegawa T; Mason AN; Noma H; Ota E
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015804. PubMed ID: 38829176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
    Rofagha S; Bhisitkul RB; Boyer DS; Sadda SR; Zhang K;
    Ophthalmology; 2013 Nov; 120(11):2292-9. PubMed ID: 23642856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Hamid MA; Abdelfattah NS; Salamzadeh J; Abdelaziz STA; Sabry AM; Mourad KM; Shehab AA; Kuppermann BD
    Int J Retina Vitreous; 2021 Apr; 7(1):26. PubMed ID: 33795022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognosis criteria of optical coherence tomography angiography for the long-term efficacy of anti-VEGF therapy of neovascular age-related macular degeneration].
    Fursova AZ; Nikulich IF; Dmitrieva EI; Gusarevich OG; Derbeneva AS; Vasilyeva MA; Kozhevnikova OS; Kolosova NG; Rabota FK
    Vestn Oftalmol; 2023; 139(6):50-58. PubMed ID: 38235630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years' Real-World Clinical Outcomes.
    Horner F; Lip PL; Mohammed BR; Fusi-Rubiano W; Gokhale E; Mushtaq B; Chavan R
    Clin Ophthalmol; 2021; 15():1703-1713. PubMed ID: 33935487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy for neovascular age-related macular degeneration.
    Evans JR; Igwe C; Jackson TL; Chong V
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004004. PubMed ID: 32844399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept.
    Barakat A; Rufin V; Tran THC
    J Fr Ophtalmol; 2018 Sep; 41(7):603-610. PubMed ID: 30166233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.